Poland· PL-100416921
Besremi
A ropeginterferon alfa-2b product containing ropeginterferonum alfa-2b, registered in Poland by AOP Orphan Pharmaceuticals GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ropeginterferon alfa-2b is registered in 12 of 19 countries.
Countries holding a registration under ATC L03AB15 (ropeginterferon alfa-2b), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Ropeginterferon alfa-2b · ATC L03AB15
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Ropeginterferonum alfa-2b
- Manufacturer
- AOP Orphan Pharmaceuticals GmbH
- Country
- Poland (PL)
- ATC code
- L03AB15
- ATC class
- Ropeginterferon alfa-2b
- Defined daily dose
- 18 mcg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin09007653000976
- gtin09007653000952
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ropeginterferon alfa-2b in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBESREMIAOP Orphan Pharmaceuticals GmbH, Wien
- BelgiumBesremi 250 µg/0.5 mlAOP Orphan Pharmaceuticals
- SwitzerlandBesremi
- SpainBESREMI 250 MICROGRAMOS/0,5 ML DE SOLUCION PARA INYECCION EN PLUMA PRECARGADAAop Orphan Pharmaceuticals Gmbh
- SwedenBesremi 250 mikrogram/0,5 ml Injektionsvätska, lösning i förfylld injektionspennaAop Orphan Pharmaceuticals GmbH
- United StatesBESREMiPharmaEssentia USA
- FinlandBesremiOrifarm Oy
- NorwayBesremiOrifarm AS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Besremi
- Liechtenstein · Besremi
- Norway · Besremi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fcdc3b4b-94d6-4e3b-b2ef-b75a7bd64711 GET /v1/drugs/fcdc3b4b-94d6-4e3b-b2ef-b75a7bd64711?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
"source": "urpl",
"strength": "250 mcg/0,5 ml",
"packaging": "09007653000976 ¦ Rpz ¦ EU/1/18/1352/001 ¦ 131363\n1 wstrzykiwacz 0,5 ml + 2 igły\n¦ UR/Z/4c/013/23 - 09007653000952\nRpz ¦ EU/1/18/1352/003 ¦ 142392\n3 wstrzykiwacze 0,5 ml +6 igieł",
"substance": "Ropeginterferonum alfa-2b 250 mcg/0,5 ml",
"common_name": "Ropeginterferonum alfa-2b",
"pl_product_id": "100416921",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ropeginterferon alfa-2b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.